While the effectiveness of GLP-1s in diabetes management is well established, coverage for weight loss presents a more complex challenge
Part of the GLP-1RA (Liraglutide, Semiglutide) has been verified to be efficacious in the treatment of fatty liver and is employed in the management of T2DM complicated with nonalcoholic fatty liver disease, primarily by ameliorating metabolic dysfunction, insulin resistance, and lipotoxicity of the organs related to its pathogenesis (61), decelerating the fibrosis process and reducing the liver fat content
HucMSC-Derived Exosomes Mitigate the Age-Related Retardation of Fertility in Female Mice
Standard therapeutic doses of GLP-1 medication can have multiple side effects, such as nausea, vomiting, diarrhea, and constipation
doi: 10.1111/j.1399-3054.1983.tb04162.x 37 NakanoY.AsadaK